Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China

Pappas, 2018, Invasive candidiasis, Nat Rev Dis Primers, 4, 18026, 10.1038/nrdp.2018.26 Delaloye, 2014, Invasive candidiasis as a cause of sepsis in the critically ill patient, Virulence, 5, 161, 10.4161/viru.26187 Chindamporn, 2018, Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia Fungal Working Group (AFWG) initiative, Med Mycol, 56, 416, 10.1093/mmy/myx066 Chen, 2018, Epidemiology of fungal infections in China, Front Med, 12, 58, 10.1007/s11684-017-0601-0 Pappas, 2016, Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 62, e1, 10.1093/cid/civ933 Martin-Loeches, 2019, ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients, Intensive Care Med, 45, 789, 10.1007/s00134-019-05599-w Jullien, 2017, Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation, J Antimicrob Chemother, 72, 181, 10.1093/jac/dkw352 Würthwein, 2013, Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis, Antimicrob Agents Chemother, 57, 1664, 10.1128/AAC.01912-12 van der Elst, 2017, Low caspofungin exposure in patients in intensive care units, Antimicrob Agents Chemother, 61, e01582, 10.1128/AAC.01582-16 Kurland, 2019, Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels, Antimicrob Agents Chemother, 63, e02466, 10.1128/AAC.02466-18 Pérez-Pitarch, 2018, Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration, Int J Antimicrob Agents, 51, 115, 10.1016/j.ijantimicag.2017.05.013 De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660 Andes, 2010, In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species, Antimicrob Agents Chemother, 54, 2497, 10.1128/AAC.01584-09 Hall, 2013, Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths, Antimicrob Agents Chemother, 57, 2259, 10.1128/AAC.01490-12 Yang, 2016, Pharmacokinetic/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations, Int J Antimicrob Agents, 47, 397, 10.1016/j.ijantimicag.2016.02.004 Puig-Asensio, 2014, Medical Mycology Study Group (GEMICOMED) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC); Spanish Network for Research in Infectious Diseases. Impact of therapeutic strategies on the prognosis of candidemia in the ICU, Crit Care Med, 42, 1423, 10.1097/CCM.0000000000000221 Fernández-Ruiz, 2014, Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis, Clin Infect Dis, 58, 1413, 10.1093/cid/ciu158 Chiotos, 2016, Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12), J Antimicrob Chemother, 71, 3536, 10.1093/jac/dkw305 Muilwijk, 2014, Pharmacokinetics of caspofungin in ICU patients, J Antimicrob Chemother, 69, 3294, 10.1093/jac/dku313 Patel, 2018, Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials, Br J Clin Pharmacol, 84, 52, 10.1111/bcp.13404 Hong, 2017, Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase, J Clin Pharmacol, 57, 652, 10.1002/jcph.849 Birmingham, 2015, Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States, Eur J Clin Pharmacol, 71, 329, 10.1007/s00228-014-1800-0 Tomita, 2013, Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism, Clin Pharmacol Ther, 94, 37, 10.1038/clpt.2012.221 Sandhu, 2005, Hepatic uptake of the novel antifungal agent caspofungin, Drug Metab Dispos, 33, 676, 10.1124/dmd.104.003244 Zhivkova, 2015, Studies on drug–human serum albumin binding: the current state of the matter, Curr Pharm Des, 21, 1817, 10.2174/1381612821666150302113710 Roberts, 2013, The clinical relevance of plasma protein binding changes, Clin Pharmacokinet, 52, 1, 10.1007/s40262-012-0018-5 Bellmann, 2017, Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients, Infection, 45, 737, 10.1007/s15010-017-1042-z Nguyen, 2007, Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit, J Antimicrob Chemother, 60, 100, 10.1093/jac/dkm125 Fasano, 2005, The extraordinary ligand binding properties of human serum albumin, IUBMB Life, 57, 787, 10.1080/15216540500404093 Meijers, 2008, A review of albumin binding in CKD, Am J Kidney Dis, 51, 839, 10.1053/j.ajkd.2007.12.035 Dong, 2019, Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: potential factors affecting the pharmacokinetic/pharmacodynamic target attainment, Basic Clin Pharmacol Toxicol, 125, 353, 10.1111/bcpt.13245 Thomson, 2009, Liver function tests’ on the intensive care unit: a prospective, observational study, Intensive Care Med, 35, 1406, 10.1007/s00134-009-1511-7 Jenniskens, 2018, Cholestatic alterations in the critically ill: some new light on an old problem, Chest, 153, 733, 10.1016/j.chest.2017.08.018 McCarty, 2013, Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues—a rationale for the versatile health protection associated with elevated plasma bilirubin, Med Hypotheses, 81, 607, 10.1016/j.mehy.2013.07.013 Otani, 2001, Increased urinary excretion of bilirubin oxidative metabolites in septic patients: a new marker for oxidative stress in vivo, J Surg Res, 96, 44, 10.1006/jsre.2000.6036 Kramer, 2007, Austrian Epidemiologic Study on Intensive Care, ASDI Study Group. Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study, Crit Care Med, 35, 1099, 10.1097/01.CCM.0000259462.97164.A0 Odell, 1959, The dissociation of bilirubin from albumin and its clinical implications, J Pediatr, 55, 268, 10.1016/S0022-3476(59)80223-7 Greenfield, 1983, Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function, Rev Infect Dis, 5, S127, 10.1093/clinids/5-Supplement_1.S127 Martial, 2016, Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure, Clin Pharmacokinet, 55, 723, 10.1007/s40262-015-0347-2 2019 2019 Xu, 2015, Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients, Int J Antimicrob Agents, 46, 631, 10.1016/j.ijantimicag.2015.08.009 Liu, 2014, China-SCAN Team. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study, J Antimicrob Chemother, 69, 162, 10.1093/jac/dkt330 Pfaller, 2017, Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program, Antimicrob Agents Chemother, 61, e02045, 10.1128/AAC.02045-16 Gioia, 2020, Pharmacokinetics of echinocandins in suspected Candida peritonitis: a potential risk for resistance, Int J Infect Dis, 101, 24, 10.1016/j.ijid.2020.09.019 Grau, 2015, Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis, J Antimicrob Chemother, 70, 2854, 10.1093/jac/dkv173